Oncolytic immunotherapy and bortezomib synergy improves survival of refractory multiple myeloma in a preclinical model

Chandini M. Thirukkumaran, Zhong Qiao Shi, Gerard J. Nuovo, Joanne Luider, Karen A. Kopciuk, Yuan Dong, Ahmed A. Mostafa, Satbir Thakur, Kathy Gratton, Ailian Yang, Alex C. Chin, Matt C. Coffey, Victor H. Jimenez-Zepeda, Douglas Stewart, Marta Chesi, Peter Leif Bergsagel, Don Morris

Research output: Contribution to journalArticle

Abstract

The oncolytic reovirus (RV) has demonstrated clinical efficacy and minimal toxicity in a variety of cancers, including multiple myeloma (MM). MM is a malignancy of plasma cells that is considered treatable but incurable because of the 90% relapse rate that is primarily from drug resistance. The systemic nature of MM and the antitumor immunosuppression by its tumor microenvironment presents an ongoing therapeutic challenge. In the present study, we demonstrate that RV synergizes with the standard-of-care MM drug bortezomib (BTZ) and, importantly, enhances its therapeutic potential in therapy-resistant human MM cell lines in vitro. Using the syngeneic Vk*MYC BTZ-resistant immunocompetent transplantable MM murine model, we also demonstrate that mice harboring BTZ-insensitive MM tumors respond to the RV/BTZ combination treatment in terms of decreased tumor burden and improved overall survival (P < .00001). We demonstrate that BTZ augments RV replication in tumor-associated endothelial cells and myeloma cells, leading to enhanced viral delivery and thereby stimulating cytokine release, immune activity, apoptosis, and reduction of the MM-associated immune suppression. We conclude that combined RV/BTZ is an attractive therapeutic strategy with no safety signals for the treatment of MM.

Original languageEnglish (US)
Pages (from-to)797-812
Number of pages16
JournalBlood advances
Volume3
Issue number5
DOIs
StatePublished - Mar 12 2019

Fingerprint

Multiple Myeloma
Immunotherapy
Survival
Neoplasms
Therapeutics
Bortezomib
Tumor Microenvironment
Standard of Care
Plasma Cells
Tumor Burden
Drug Resistance
Immunosuppression
Endothelial Cells
Apoptosis
Cytokines
Safety
Recurrence
Cell Line
Pharmaceutical Preparations

Cite this

Thirukkumaran, C. M., Shi, Z. Q., Nuovo, G. J., Luider, J., Kopciuk, K. A., Dong, Y., ... Morris, D. (2019). Oncolytic immunotherapy and bortezomib synergy improves survival of refractory multiple myeloma in a preclinical model. Blood advances, 3(5), 797-812. https://doi.org/10.1182/bloodadvances.2018025593

Oncolytic immunotherapy and bortezomib synergy improves survival of refractory multiple myeloma in a preclinical model. / Thirukkumaran, Chandini M.; Shi, Zhong Qiao; Nuovo, Gerard J.; Luider, Joanne; Kopciuk, Karen A.; Dong, Yuan; Mostafa, Ahmed A.; Thakur, Satbir; Gratton, Kathy; Yang, Ailian; Chin, Alex C.; Coffey, Matt C.; Jimenez-Zepeda, Victor H.; Stewart, Douglas; Chesi, Marta; Bergsagel, Peter Leif; Morris, Don.

In: Blood advances, Vol. 3, No. 5, 12.03.2019, p. 797-812.

Research output: Contribution to journalArticle

Thirukkumaran, CM, Shi, ZQ, Nuovo, GJ, Luider, J, Kopciuk, KA, Dong, Y, Mostafa, AA, Thakur, S, Gratton, K, Yang, A, Chin, AC, Coffey, MC, Jimenez-Zepeda, VH, Stewart, D, Chesi, M, Bergsagel, PL & Morris, D 2019, 'Oncolytic immunotherapy and bortezomib synergy improves survival of refractory multiple myeloma in a preclinical model', Blood advances, vol. 3, no. 5, pp. 797-812. https://doi.org/10.1182/bloodadvances.2018025593
Thirukkumaran, Chandini M. ; Shi, Zhong Qiao ; Nuovo, Gerard J. ; Luider, Joanne ; Kopciuk, Karen A. ; Dong, Yuan ; Mostafa, Ahmed A. ; Thakur, Satbir ; Gratton, Kathy ; Yang, Ailian ; Chin, Alex C. ; Coffey, Matt C. ; Jimenez-Zepeda, Victor H. ; Stewart, Douglas ; Chesi, Marta ; Bergsagel, Peter Leif ; Morris, Don. / Oncolytic immunotherapy and bortezomib synergy improves survival of refractory multiple myeloma in a preclinical model. In: Blood advances. 2019 ; Vol. 3, No. 5. pp. 797-812.
@article{28ae05862af04ebfb8d4a585b9ff1a68,
title = "Oncolytic immunotherapy and bortezomib synergy improves survival of refractory multiple myeloma in a preclinical model",
abstract = "The oncolytic reovirus (RV) has demonstrated clinical efficacy and minimal toxicity in a variety of cancers, including multiple myeloma (MM). MM is a malignancy of plasma cells that is considered treatable but incurable because of the 90{\%} relapse rate that is primarily from drug resistance. The systemic nature of MM and the antitumor immunosuppression by its tumor microenvironment presents an ongoing therapeutic challenge. In the present study, we demonstrate that RV synergizes with the standard-of-care MM drug bortezomib (BTZ) and, importantly, enhances its therapeutic potential in therapy-resistant human MM cell lines in vitro. Using the syngeneic Vk*MYC BTZ-resistant immunocompetent transplantable MM murine model, we also demonstrate that mice harboring BTZ-insensitive MM tumors respond to the RV/BTZ combination treatment in terms of decreased tumor burden and improved overall survival (P < .00001). We demonstrate that BTZ augments RV replication in tumor-associated endothelial cells and myeloma cells, leading to enhanced viral delivery and thereby stimulating cytokine release, immune activity, apoptosis, and reduction of the MM-associated immune suppression. We conclude that combined RV/BTZ is an attractive therapeutic strategy with no safety signals for the treatment of MM.",
author = "Thirukkumaran, {Chandini M.} and Shi, {Zhong Qiao} and Nuovo, {Gerard J.} and Joanne Luider and Kopciuk, {Karen A.} and Yuan Dong and Mostafa, {Ahmed A.} and Satbir Thakur and Kathy Gratton and Ailian Yang and Chin, {Alex C.} and Coffey, {Matt C.} and Jimenez-Zepeda, {Victor H.} and Douglas Stewart and Marta Chesi and Bergsagel, {Peter Leif} and Don Morris",
year = "2019",
month = "3",
day = "12",
doi = "10.1182/bloodadvances.2018025593",
language = "English (US)",
volume = "3",
pages = "797--812",
journal = "Blood advances",
issn = "2473-9529",
publisher = "American Society of Hematology",
number = "5",

}

TY - JOUR

T1 - Oncolytic immunotherapy and bortezomib synergy improves survival of refractory multiple myeloma in a preclinical model

AU - Thirukkumaran, Chandini M.

AU - Shi, Zhong Qiao

AU - Nuovo, Gerard J.

AU - Luider, Joanne

AU - Kopciuk, Karen A.

AU - Dong, Yuan

AU - Mostafa, Ahmed A.

AU - Thakur, Satbir

AU - Gratton, Kathy

AU - Yang, Ailian

AU - Chin, Alex C.

AU - Coffey, Matt C.

AU - Jimenez-Zepeda, Victor H.

AU - Stewart, Douglas

AU - Chesi, Marta

AU - Bergsagel, Peter Leif

AU - Morris, Don

PY - 2019/3/12

Y1 - 2019/3/12

N2 - The oncolytic reovirus (RV) has demonstrated clinical efficacy and minimal toxicity in a variety of cancers, including multiple myeloma (MM). MM is a malignancy of plasma cells that is considered treatable but incurable because of the 90% relapse rate that is primarily from drug resistance. The systemic nature of MM and the antitumor immunosuppression by its tumor microenvironment presents an ongoing therapeutic challenge. In the present study, we demonstrate that RV synergizes with the standard-of-care MM drug bortezomib (BTZ) and, importantly, enhances its therapeutic potential in therapy-resistant human MM cell lines in vitro. Using the syngeneic Vk*MYC BTZ-resistant immunocompetent transplantable MM murine model, we also demonstrate that mice harboring BTZ-insensitive MM tumors respond to the RV/BTZ combination treatment in terms of decreased tumor burden and improved overall survival (P < .00001). We demonstrate that BTZ augments RV replication in tumor-associated endothelial cells and myeloma cells, leading to enhanced viral delivery and thereby stimulating cytokine release, immune activity, apoptosis, and reduction of the MM-associated immune suppression. We conclude that combined RV/BTZ is an attractive therapeutic strategy with no safety signals for the treatment of MM.

AB - The oncolytic reovirus (RV) has demonstrated clinical efficacy and minimal toxicity in a variety of cancers, including multiple myeloma (MM). MM is a malignancy of plasma cells that is considered treatable but incurable because of the 90% relapse rate that is primarily from drug resistance. The systemic nature of MM and the antitumor immunosuppression by its tumor microenvironment presents an ongoing therapeutic challenge. In the present study, we demonstrate that RV synergizes with the standard-of-care MM drug bortezomib (BTZ) and, importantly, enhances its therapeutic potential in therapy-resistant human MM cell lines in vitro. Using the syngeneic Vk*MYC BTZ-resistant immunocompetent transplantable MM murine model, we also demonstrate that mice harboring BTZ-insensitive MM tumors respond to the RV/BTZ combination treatment in terms of decreased tumor burden and improved overall survival (P < .00001). We demonstrate that BTZ augments RV replication in tumor-associated endothelial cells and myeloma cells, leading to enhanced viral delivery and thereby stimulating cytokine release, immune activity, apoptosis, and reduction of the MM-associated immune suppression. We conclude that combined RV/BTZ is an attractive therapeutic strategy with no safety signals for the treatment of MM.

UR - http://www.scopus.com/inward/record.url?scp=85062599750&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062599750&partnerID=8YFLogxK

U2 - 10.1182/bloodadvances.2018025593

DO - 10.1182/bloodadvances.2018025593

M3 - Article

C2 - 30850386

AN - SCOPUS:85062599750

VL - 3

SP - 797

EP - 812

JO - Blood advances

JF - Blood advances

SN - 2473-9529

IS - 5

ER -